Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing cancer patient care through the development of highly differentiated IL-2 targeting monoclonal antibodies. Using artificial intelligence and machine learning, the company designs innovative therapeutics aimed at enhancing immune activation against solid tumors while reducing toxicity and immunosuppression. Their lead candidate, AU-007, is a computationally designed human antibody that harnesses IL-2 to induce tumor killing with improved safety and efficacy. The company is working to revolutionize cancer patient care through best-in-class IL-2 therapeutics that direct patients’ immune systems toward killing tumor cells, leveraging AI and antibody development expertise.
Industries
Nr. of Employees
small (1-50)
Aulos Bioscience
700 Larkspur Landing Circle, Suite 108, Larkspur, CA 94939
Patents
Products
Investigational IL‑2–targeting monoclonal antibody (clinical-stage)
A computationally designed human IgG1 monoclonal antibody engineered to modulate interleukin-2 signaling by selectively blocking an epitope associated with CD25 binding, with the aim of redirecting IL‑2 activity toward effector immune cells while limiting regulatory T cell expansion and vascular toxicities.
Investigational IL‑2–targeting monoclonal antibody (clinical-stage)
A computationally designed human IgG1 monoclonal antibody engineered to modulate interleukin-2 signaling by selectively blocking an epitope associated with CD25 binding, with the aim of redirecting IL‑2 activity toward effector immune cells while limiting regulatory T cell expansion and vascular toxicities.
Services
Negotiation and execution of collaboration and supply agreements to enable combination therapy evaluation and resource sharing in clinical cohorts.
Sponsor-led management of Phase 1/2 clinical programs including protocol design, dose-escalation and expansion cohorts, safety monitoring, multi-site enrollment, and collection of PK/PD and efficacy data.
Negotiation and execution of collaboration and supply agreements to enable combination therapy evaluation and resource sharing in clinical cohorts.
Sponsor-led management of Phase 1/2 clinical programs including protocol design, dose-escalation and expansion cohorts, safety monitoring, multi-site enrollment, and collection of PK/PD and efficacy data.
Expertise Areas
- Immuno-oncology
- Computational antibody engineering
- Preclinical tumor pharmacology
- Translational immunology and biomarker analysis
Key Technologies
- Machine learning–driven antibody design
- Therapeutic monoclonal antibodies (IgG1 format)
- In vivo tumor models
- Nonclinical primate toxicology studies
News & Updates
Aulos Bioscience announced dosing of its first patient with AU-007, nivolumab, and low-dose aldesleukin in a Phase 2 cohort for melanoma treatment. The study evaluates AU-007 in combination with checkpoint inhibitors, with preliminary data expected later in 2025.
The company shared positive interim Phase 2 data showing durable tumor responses in patients with advanced cancers, including melanoma and renal cell carcinoma, treated with AU-007 and low-dose aldesleukin.
Progression to Phase 2 of clinical trial for AU-007
Aulos Bioscience has advanced AU-007 to the Phase 2 portion of its Phase 1/2 clinical trial after demonstrating safety and early anti-tumor activity.
Preclinical data demonstrating tumor eradication with AU-007
Preclinical studies show AU-007's ability to eliminate solid tumors in murine models, supporting its potential as a best-in-class IL-2 therapeutic.
Aulos Bioscience announced dosing of its first patient with AU-007, nivolumab, and low-dose aldesleukin in a Phase 2 cohort for melanoma treatment. The study evaluates AU-007 in combination with checkpoint inhibitors, with preliminary data expected later in 2025.
The company shared positive interim Phase 2 data showing durable tumor responses in patients with advanced cancers, including melanoma and renal cell carcinoma, treated with AU-007 and low-dose aldesleukin.
Progression to Phase 2 of clinical trial for AU-007
Aulos Bioscience has advanced AU-007 to the Phase 2 portion of its Phase 1/2 clinical trial after demonstrating safety and early anti-tumor activity.
Preclinical data demonstrating tumor eradication with AU-007
Preclinical studies show AU-007's ability to eliminate solid tumors in murine models, supporting its potential as a best-in-class IL-2 therapeutic.